UBS Group Upgrades Nanobiotix (NASDAQ:NBTX) to "Hold"

Nanobiotix (NASDAQ:NBTX - Get Free Report) was upgraded by analysts at UBS Group to a "hold" rating in a research report issued on Monday,Zacks.com reports.

Nanobiotix Price Performance

Shares of NBTX traded down $0.20 during trading hours on Monday, hitting $3.75. The company had a trading volume of 6,228 shares, compared to its average volume of 8,634. The business has a fifty day moving average of $3.33 and a 200-day moving average of $4.14. Nanobiotix has a 12 month low of $2.76 and a 12 month high of $7.51.

Hedge Funds Weigh In On Nanobiotix

Several institutional investors and hedge funds have recently made changes to their positions in NBTX. Geode Capital Management LLC bought a new position in Nanobiotix during the 4th quarter worth $29,000. Millennium Management LLC bought a new position in Nanobiotix during the fourth quarter worth about $39,000. Jane Street Group LLC bought a new position in Nanobiotix during the fourth quarter worth about $73,000. Finally, OLD Mission Capital LLC bought a new stake in Nanobiotix in the 4th quarter valued at about $139,000. Institutional investors and hedge funds own 38.81% of the company's stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.